About this trial
The term post-acute COVID-19 syndrome or Long COVID is a disabling syndrome that persists beyond the 3-month convalescence period after COVID-19 infections.
This syndrome affects mostly women (\~80%), present with chronic tachycardia and Orthostatic intolerance symptoms without any identifiable cause. In addition, non-specific symptoms such as fatigue, headache, and "brain fog", commonly described in POTS patients are also present in this novel condition, recently named post-COVID-19 tachycardia syndrome, POTS variant.
Reduced Vagal activity and unresolved inflammation is post-COVID-19 POTS is hypothesized as the cause of Long COVID
Eligibility criteria
Qualifiers
Prior RT-PCR-confirmed COVID-19 infection.
Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (>30 bpm) and chronic (>3 months) pre-syncopal symptoms.
Disqualifiers
Heart Disease: Myocardial Infarction, angina, heart failure
History of stroke, or transient ischemic attack
Undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries)
Uncontrolled hypertension defined as persistent blood pressure >140/90.
Trial design
Treatments tested in this trial
- Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls
- Levels of inflammatory cytokine ( IL-6) in controls
- Effect on inflammation after chronic PNS stimulation
Treatment groups
Sponsors and collaborators
Vanderbilt University Medical Center
Lead sponsor
American Heart Association
Collaborator